Educational intervention on prostate cancer in patients aged 50 and over
Abstract
Introduction: It is necessary to educate the male population about prostate cancer to achieve an early diagnosis and timely treatment. Increasing knowledge in this regard is essential for a better prognosis.
Objective: To describe the results of an educational intervention on prostate cancer in patients aged 50 years and older.
Methods: An educational intervention was carried out in patients aged 50 years and older, between August 2020 and August 2023. The sample consisted of 80 patients. The variables used were: age, educational level, occupation, knowledge level about the disease and its risk factors; the scale of sufficient and insufficient was used.
Results: Most of the patients belonged to the group between 50 and 59 years old 52 (65%). They were workers 37 (46.3%). The most represented educational level was pre-university 24 (30%). Before the educational intervention, 68 (85%) participants had insufficient knowledge of the general characteristics of the disease. After the educational intervention, the knowledge level increased to sufficient in almost all participants, 77 (96.3%). Before the intervention, the majority of participants, 52 (65%), had insufficient knowledge of the modifiable risk factors of the disease. After the intervention, the knowledge level increased to sufficient in 70 (87.5%).
Conclusions: The results of the educational intervention show that it achieved its objective, with a significant increase in knowledge related to prostate cancer.
DeCS: PROSTATIC NEOPLASMS; EDUCATION; AGE GROUPS; HEALTH EDUCATION; QUALITY OF LIFE.
Downloads
References
1 de Paula Nascente EP, Amorim RL, Fonseca-Alves CE, Dignani de Moura VM. Comparative Pathobiology of Canine and Human Prostate Cancer: State of the Art and Future Directions. Cancers (Basel) [Internet]. 2022 [citado 25 Ago 2024]; 14(11): [aprox. 5 p.]. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9179314/.
2 Muñoz-Moreno L, Carmena MJ, Prieto JC, Schally AV, Bajo AM. Tumorigenic transformation of human prostatic epithelial cell line RWPE-1 by growth hormone-releasing hormone (GHRH). Prostate [Internet]. 2022 [citado 25 Ago 2024]; 82(8): [aprox. 8 p.]. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9310601/.
3 Rojas PA, García-Bloj B, Elias E, Marchant F. Actualización en detección precoz del cáncer de próstata. Revista Médica Clínica Las Condes [Internet]. 2024 [citado 25 Ago 2024]; 35(2): 88-94. Disponible en: https://www.elsevier.es/es-revista-revista-medica-clinica-las-condes-202-articulo-actualizacion-deteccion-precoz-del-cancer-S0716864024000142
4 Pereira Suárez AL, Villegas Pineda JC, Ramírez de Arellano Sánchez JA. Un nuevo horizonte en la lucha contra el cáncer de próstata. Evid [Internet]. 2024 [citado 25 Ago 2024];(3):7-9. Disponible en: https://conevidencia.cucs.udg.mx/index.php/conevidencia/article/view/47
5 Tarrar TA, Anwar MY, Ali MA, Saeed M, Rehman S, Bajwa SF; et al. Current Status of Monoclonal Antibodies-Based Therapies in Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis of Clinical Trials. Cureus [Internet]. 2022 [citado 25 agosto 2024];14(3):e22942. Available from: https://pubmed.ncbi.nlm.nih.gov/35411277/
6 Bergengren O, Pekalaa KR, Matsoukasc K, Fainberga J, Mungovand SF, Bratte O; et al. Update on Prostate Cancer Epidemiology and Risk Factors- A Systematic Review. Eur Urol. [Internet]. 2023 [citado 25 agosto 2024]; 84(2): 191–206. Disponible en: https://pubmed.ncbi.nlm.nih.gov/37202314/
7 von Amsberg G, Alsdorf W, Karagiannis P, Coym A, Kaune M, Werner S; et al. Immunotherapy in Advanced Prostate Cancer-Light at the End of the Tunnel? Int J Mol Sci [Internet]. 2022 [citado 25 Agosto 2024]; 23(5): [aprox. 4 p.]. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8910587/.
8 Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I; et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. [Internet]. 2024 [citado 25 agosto 2024];74(3):229-263. Disponible en: https://pubmed.ncbi.nlm.nih.gov/38572751/
9 Tang DG. Understanding and targeting prostate cancer cell heterogeneity and plasticity. Semin Cancer Biol [Internet]. 2022 [citado 25 agosto 2024]; 82: [aprox. 3 p.]. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9106849
10 Verdecia-Rodríguez H, López-Peñalver M. Caracterización clínica epidemiológica del cáncer de próstata. Revista Estudiantil HolCien [Internet]. 2024 [citado 25 Ago 2024]; 5(1) Disponible en: https://revholcien.sld.cu/index.php/holcien/article/view/350
11 World Health Organization [Internet]. Francia: International Agency for Research on Cancer; 1965-2025 [update 202 5, citado 25 Agosto 2024]. Global Cancer Observatory. Cancer Today; [about 2 screens]; Disponible en: https://gco.iarc.who.int/media/globocan/factsheets/populations/152-chile-fact-sheet.pdf
12 Ministerio de Salud Pública. Anuario Estadístico de Salud 2023. Edición 2024 [Internet]. La Habana: MINSAP; 2024 [citado 3 Nov 2024] Disponible en: https://files.sld.cu/dne/files/2024/09/Anuario-Estadístico-de-Salud-2023-EDICION-2024.pdf
13 World Medical Association. World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. JAMA [Internet]. 2013 [citado 8 junio 2024];310(20):2191–2194. Disponible en: https://jamanetwork.com/journals/jama/fullarticle/2825290
14 García KP, Paneca BR, Carbajal CC, Viamontes CA. Intervención educativa sobre cáncer de próstata en población masculina entre 40 a 60 años. Arch méd Camagüey [Internet]. 2018 [citado 25 Ago 2024]; 22(1): [aprox. 3 p.]. Disponible en: https://www.medigraphic.com/cgi-bin/new/resumen.cgi?IDARTICULO=80305.
15 Fernández Marichal FS, Toirán García R, Varela Álvarez A, Segura Roque O. Cáncer prostático: correlación entre el valor del antígeno prostático específico y el resultado anatomoclínico. Arch méd Camagüey [Internet]. 2015 [citado 25 Ago 2024]; 19(1): [aprox. 7 p.]. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S102502552015000100008&lang=es.
16 Villegas CR, Chacón JA, Sánchez T. Sobrevida en cáncer de próstata de una población del centro de Colombia. Acta Med Colomb [Internet]. 2015 [citado 25 Ago 2024]; 40(2): [aprox. 2 p.]. Disponible en: http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S012024482015000200006&lang=es.
17 Rodríguez Puga R, Dueñas Rodríguez Y. Intervención educativa sobre el examen y autoexamen de próstata en pacientes mayores de 45 años. Rev cuban Med [Internet]. 2023 [citado 25 Feb 2025];62(4): e3396. Disponible en: https://revmedicina.sld.cu/index.php/med/article/view/3396
18 Dueñas Rodríguez Y, Rodríguez Puga R, MacDonald Ruano RD, Pérez Díaz Y. Efectividad de una intervención psicoeducativa sobre el cáncer de próstata en trabajadores de la salud. Acta Médica [Internet]. 2023 [citado 25 Feb 2025]; 24(2): e367. Disponible en: https://revactamedica.sld.cu/index.php/act/article/view/367
19 Hernández Sánchez Y. Intervención educativa sobre el cáncer de próstata. Comunidad Felicia 2 Urbano Noris, 2019 [tesis]. Holguín-Cuba: Universidad de Ciencias Médicas de Holguín; 2021. Disponible en: https://tesis.hlg.sld.cu/index.php?P=FullRecord&ResourceId=2019
20 Hidalgo Infante BA, Doreyis A, Navaza B, Arias Figueira O. Intervención educativa sobre cáncer de próstata. Unidad cerrada del MININT. Marzo 2021-diciembre 2021. JORCIENCIAPDCL [Internet]. 2022 [citado 25 Ago 2024]. Disponible en: https://jorcienciapdcl.sld.cu/index.php/jorcienciapdcl22/2022/paper/view/253/215
21 Islas Pérez LÁ, Martínez Reséndiz JI, Ruiz Hernández A, Ruvalcaba Ledezma JC, Benítez Medina A, Beltrán Rodríguez MG; et al. Epidemiología del cáncer de próstata, sus determinantes y prevención. JONNPR [Internet]. 2020 [citado 25 Ago 2024]; 5(9): [aprox. 2 p.]. Disponible en: http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S2529850X2020000901010&lang=es

Published
How to Cite
Issue
Section
License
Copyright: Camagüey Medical Archive Magazine, offers immediately after being indexed in the SciELO Project; Open access to the full text of the articles under the principle of making available and free the research to promote the exchange of global knowledge and contribute to a greater extension, publication, evaluation and extensive use of the articles that can be used without purpose As long as reference is made to the primary source.
Conflicts of interest: authors must declare in a mandatory manner the presence or not of conflicts of interest in relation to the investigation presented.
(Download Statement of potential conflicts of interest)
The Revista Archivo Médico de Camagüey is under a License Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 International (CC BY 4.0).
This license allows others to distribute, to mix, to adjust and to build from its work, even for commercial purposes, as long as it is recognized the authorship of the original creation. This is the most helpful license offered. Recommended for maximum dissemination and use of licensed materials. The full license can be found at: https://creativecommons.org/licenses/